Can sorafenib be stopped? If the drug is discontinued, will the patient require alternative treatment?

Sorafenib is a multi-target tyrosine kinase inhibitor (TKI), mainly used to treat malignant tumors such as hepatocellular carcinoma (HCC), renal cell carcinoma (RCC) and thyroid cancer. For patients who are taking sorafenib, whether the drug can be discontinued needs to be determined based on multiple factors such as disease progression, drug response, and side effects. Under normal circumstances, doctors will adjust the treatment plan according to the patient's specific situation, and patients should not stop taking the medicine on their own to avoid affecting the treatment effect or causing rapid progression of the disease.

If a patient needs to discontinue sorafenib due to poor efficacy or disease progression, it is usually necessary to switch to other targeted drugs or systemic treatments. For example, for patients with liver cancer, if the disease still progresses after sorafenib treatment, doctors may recommend the use of lenvatinib (Lenvatinib), regorafenib (Regorafenib) or PD-1/PD-L1 immunotherapy. For patients with kidney cancer, common alternatives include pazopanib (Pazopanib), axitinib (Axitinib) or immune combination therapy. These alternative treatments can help slow disease progression and improve patient survival.

Some patients may consider discontinuing the drug due to serious side effects (such as hand-foot skin reaction, hypertension, or gastrointestinal adverse reactions). In this case, doctors usually first adjust the dose or take symptomatic treatment, such as lowering the dose, discontinuing the drug intermittently, or using drugs to alleviate side effects. If the side effects are still intolerable, other treatment options may be considered. Therefore, appropriate management of side effects is crucial for long-term use of sorafenib.

In general, the decision to discontinue sorafenib needs to be made under the guidance of a physician, and the best plan should be formulated based on the patient's condition, tolerance, and available alternative treatments. Whether switching to other targeted drugs, combining immunotherapy, or adjusting treatment strategies, personalized selection needs to be made based on the patient's specific situation to ensure the continuity and effectiveness of treatment. Patients must fully communicate with their doctors before discontinuing or changing medications to avoid adverse effects caused by disease progression or treatment interruption.

Reference materials:https://www.nexavar.com/